Adverum Biotechnologies, Inc. announced that Romuald Corbau, Ph.D., has joined Adverum as the company?s chief scientific officer. Dr. Corbau will serve as a member of Adverum?s executive committee. Dr. Corbau has over 25 years of industry experience ranging from startups to global pharmaceutical companies in the United States and Europe.

Dr. Corbau joins Adverum from GenEdit, where he served as Chief Scientific Officer. Prior to joining GenEdit, Dr. Corbau progressed from Vice President of Research to Chief Scientific Officer at Freeline. Prior to Freeline, Dr. Corbau was Translational Lead at Spark Therapeutics, where his Translational department was focused on AAV sub-retinal injection gene therapy approaches for ocular indications, as well as Spark Therapeutics?

CNS and systemic, liver-directed therapies. Before joining Spark Therapeutics, Dr. Corbau held various research positions at Pfizer in the UK, CISTIM (The Centre for Innovation and Stimulation of Drug Discovery) in Belgium, and Children?s Hospital of Philadelphia. Dr. Corbau earned his M.A. in Biochemistry from Lille University and his Ph.D. from L'Institut national de la santé et de la recherche médicale (INSERM) in Heidelberg, Germany.